Gastroesophageal Adenocarcinoma Market is Expected to Showcase a Significant Growth During the Forecast Period (2022-2032), Predicts DelveInsight

February 28 02:12 2023
Gastroesophageal Adenocarcinoma Market is Expected to Showcase a Significant Growth During the Forecast Period (2022-2032), Predicts DelveInsight
Delveinsight Business Research LLP
DelveInsight’s “Gastroesophageal Adenocarcinoma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Gastroesophageal Adenocarcinoma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Gastroesophageal Adenocarcinoma market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Gastroesophageal Adenocarcinoma Market

Gastroesophageal Adenocarcinoma: An Overview

Gastroesophageal junction adenocarcinoma begins in the glandular cells located near the GE junction and has also been referred to as ‘esophagogastric junction adenocarcinoma. Adenocarcinoma, at the EG junction, is located in the distal third of the esophagus (C15.5 in the ICD classification of tumors) or in the proximal part of the stomach or cardia (C16.0). In most countries, there are much more cases of cardia, than in the distal esophagus.

Siewert et al. classified cancer at the EG junction into 3 groups with respect to the central point of the tumor: Group I with an esophageal origin, Group II with an origin in the gastric cardia, and Group III with a sub-cardiac origin. The risk factors of the disease include Gastroesophageal reflux disease and Barrett’s esophagus, and other than this, smoking and tobacco use also increases the risk.

HER2 overexpression/amplification has been the first predictive biomarker approved in clinical practice to guide patient selection for targeted treatment with trastuzumab in advanced gastric and gastroesophageal junction cancers. More recently, immunotherapy has been approved for the treatment of GEA, and PD-L1 expression is now a biomarker required for the administration of pembrolizumab in these diseases

Gastroesophageal Adenocarcinoma Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Gastroesophageal Adenocarcinoma market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Gastroesophageal Adenocarcinoma market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Gastroesophageal Adenocarcinoma Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Gastroesophageal Adenocarcinoma Epidemiology Segmented as –

  • Total incidence of Gastroesophageal Junction Adenocarcinoma in the 7MM (2019–2032)

  • Gender-specific cases of Gastroesophageal Junction Adenocarcinoma in the 7MM (2019–2032)

  • Biomarker-specific cases of Gastroesophageal Junction Adenocarcinoma in the 7MM (2019–2032)

Learn How the Gastroesophageal Adenocarcinoma Market Will Evolve and Grow by 2032 @

Gastroesophageal Adenocarcinoma Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Gastroesophageal Adenocarcinoma market or expected to be launched during the study period. The analysis covers the Gastroesophageal Adenocarcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Gastroesophageal Adenocarcinoma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Gastroesophageal Adenocarcinoma Therapeutics Assessment 

Gastroesophageal Junction adenocarcinomas (GEJAC) represent a severe global health burden, and despite improvements in the multimodality treatment of these malignancies, the prognosis of patients remains poor.

Treatment of locally advanced GEJ tumors presents a unique challenge because these tumors have generally been approached as either esophageal or gastric cancers, and thus optimal preoperative management remains uncertain. Both neoadjuvant chemoradiation and perioperative chemotherapy have been widely adopted in standard practice; however, it is unclear which approach offers the optimal outcome for the fit patient capable of receiving any planned strategy.

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Gastroesophageal Adenocarcinoma Competitive Intelligence Analysis

4. Gastroesophageal Adenocarcinoma Market Overview at a Glance

5. Gastroesophageal Adenocarcinoma Disease Background and Overview

6. Gastroesophageal Adenocarcinoma Patient Journey

7. Gastroesophageal Adenocarcinoma Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Gastroesophageal Adenocarcinoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Gastroesophageal Adenocarcinoma Unmet Needs

10. Key Endpoints of Gastroesophageal Adenocarcinoma Treatment

11. Gastroesophageal Adenocarcinoma Marketed Products

12. Gastroesophageal Adenocarcinoma Emerging Drugs and Latest Therapeutic Advances

13. Gastroesophageal Adenocarcinoma Seven Major Market Analysis

14. Attribute Analysis

15. Gastroesophageal Adenocarcinoma Market Outlook (In US, EU5, and Japan)

16. Gastroesophageal Adenocarcinoma Access and Reimbursement Overview

17. KOL Views on the Gastroesophageal Adenocarcinoma Market

18. Gastroesophageal Adenocarcinoma Market Drivers

19. Gastroesophageal Adenocarcinoma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @


Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Services and Solutions

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States